Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2101 to 2115 of 8880 results

  1. Transvaginal Ultrasound-Guided Radiofrequency Ablation (RFA) for Uterine Fibroids

    Awaiting development Reference number: GID-HTG10171 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  2. Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions

    Awaiting development Reference number: GID-HTG10170 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  3. CM-AT for behaviours associated with autism in children and young people [ID6731]

    Awaiting development Reference number: GID-TA11955 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. CT hepatic arteriography for patients undergoing percutaneous ablation of primary or secondary liver tumours

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  5. Ponatinib for treating recurrent or refractory chronic myeloid leukaemia in people 1 to 17 years when another tyrosine kinase inhibitor is unsuitable [TSID12041]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Deucravacitinib for treating active Sjogren's syndrome [ID6715]

    Awaiting development Reference number: GID-TA11939 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Selinexor with ruxolitinib for treating splenomegaly or symptoms in myelofibrosis untreated with a JAK inhibitor [ID6717]

    Awaiting development Reference number: GID-TA11941 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Selinexor with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 to 4 treatment lines in people who have not had pomalidomide [ID6705]

    Awaiting development Reference number: GID-TA11938 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Riliprubart for treating chronic inflammatory demyelinating polyneuropathy [TSID12314]

    Awaiting development Reference number: GID-TA11917 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Renal cell carcinoma Pathways Pilot [ID6186]

    In development Reference number: GID-TA11186 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Social work interventions for adults with complex needs (including learning disabilities) and mental health needs

    Awaiting development Reference number: GID-QS10148 Expected publication date: TBC

    Quality standard
    Awaiting development

  12. Acne

    Awaiting development Reference number: GID-QS10036 Expected publication date: TBC

    Quality standard
    Awaiting development

  13. PLX-PAD for treating muscle injury after arthroplasty for hip fracture in people 60 to 90 years [ID3989]

    Awaiting development Reference number: GID-TA10885 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955]

    Awaiting development Reference number: GID-TA10867 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]

    Awaiting development Reference number: GID-TA10657 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development